Seeking Alpha
24 Dec 2025, 14:00 UTC · 46w ago
Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal
Impact · against what's priced in
Olema Pharmaceuticals receives a valuation lift from the transition of palazestrant into pivotal phase 3 trials for first-line treatment and positive combination data with KISQALI. While the regulatory path is several years away, the expansion into a larger addressable market and efficacy in endocrine-resistant tumors provide a concrete growth catalyst.
- OLMA+0.70
No priced-in read yet





